Cadila Healthcare at new high on getting EIR from USFDA for Baddi facility

In past eight trading days, the stock gain 17% as compared to 1.8% rise in the S&P BSE Sensex

Cadila Healthcare hit a new high of Rs 510, up 4% on BSE in early morning deals, after the company received Establishment Inspection Report (EIR) from the US health regulator for its Baddi facility in Himachal Pradesh.

"The company's manufacturing facility at Baddi has received an Establishment Inspection Report from the United States Food and Drug Administration (USFDA)", Cadila Healthcare said in a BSE filing.

This receipt of EIR indicates successful closure of 483s raised based on the inspection carried out between February 21 to March 1, 2017, it added.

In separate regulatory filing, the company said